Cooley Advises Capstan In Sale To AbbVie Worth Up To $2.1B

Pharma giant AbbVie Inc. announced Monday that it would pay up to $2.1 billion to acquire cell therapy developer Capstan Therapeutics Inc., which Cooley LLP is advising in the deal aimed...

Already a subscriber? Click here to view full article